Adolfo A Ferrando

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5369200/publications.pdf

Version: 2024-02-01

124	12,148	66343	30922
papers	citations	42 h-index	102 g-index

124	124	124	16397
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia. Science, 2004, 306, 269-271.	12.6	2,494
2	Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524.	27.8	749
3	NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18261-18266.	7.1	745
4	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature Genetics, 2014, 46, 166-170.	21.4	534
5	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. Journal of Experimental Medicine, 2007, 204, 1825-1835.	8.5	427
6	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nature Medicine, 2014, 20, 1130-1137.	30.7	349
7	The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nature Reviews Cancer, 2016, 16, 494-507.	28.4	348
8	A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature Medicine, 2019, 25, 1938-1947.	30.7	348
9	Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature, 2014, 514, 513-517.	27.8	340
10	The mutational landscape of cutaneous T cell lymphoma and SÃ©zary syndrome. Nature Genetics, 2015, 47, 1465-1470.	21.4	322
11	Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Medicine, 2013, 19, 368-371.	30.7	304
12	Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood, 2003, 102, 262-268.	1.4	298
13	PHF6 mutations in T-cell acute lymphoblastic leukemia. Nature Genetics, 2010, 42, 338-342.	21.4	282
14	The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability. Cell, 2013, 153, 1552-1566.	28.9	277
15	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	6.4	237
16	Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell, 2013, 24, 766-776.	16.8	220
17	CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. Cancer Cell, 2015, 27, 755-768.	16.8	216
18	Multivalent Small-Molecule Pan-RAS Inhibitors. Cell, 2017, 168, 878-889.e29.	28.9	213

#	Article	IF	Citations
19	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nature Medicine, 2015, 21, 1182-1189.	30.7	180
20	How I treat T-cell acute lymphoblastic leukemia in adults. Blood, 2015, 126, 833-841.	1.4	179
21	The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. Blood, 2017, 129, 1124-1133.	1.4	174
22	The role of NOTCH1 signaling in T-ALL. Hematology American Society of Hematology Education Program, 2009, 2009, 353-361.	2.5	167
23	RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. Cancer Cell, 2018, 33, 259-273.e7.	16.8	154
24	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11306-11311.	7.1	151
25	Negative feedbackâ€“defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nature Medicine, 2015, 21, 563-571.	30.7	141
26	Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nature Medicine, 2012, 18, 436-440.	30.7	138
27	Gene expression profiling in T-cell acute lymphoblastic leukemia. Seminars in Hematology, 2003, 40, 274-280.	3.4	124
28	Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood, 2004, 103, 1909-1911.	1.4	117
29	WT1 mutations in T-ALL. Blood, 2009, 114, 1038-1045.	1.4	111
30	Therapeutic Effect of Î³-Secretase Inhibition in KrasG12V-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK. Cancer Cell, 2012, 22, 222-234.	16.8	108
31	Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2911-E2919.	7.1	108
32	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 764-769.	7.1	100
33	Clonal evolution in leukemia. Nature Medicine, 2017, 23, 1135-1145.	30.7	93
34	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature, 2018, 553, 511-514.	27.8	90
35	Pharmacological inhibition of the transcription factor PU.1 in leukemia. Journal of Clinical Investigation, 2017, 127, 4297-4313.	8.2	89
36	Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	9.4	83

#	Article	IF	Citations
37	Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. Cancer Discovery, 2019, 9, 436-451.	9.4	67
38	Therapeutic Targeting of NOTCH1 Signaling in T-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma and Myeloma, 2009, 9, S205-S210.	1.4	64
39	Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. Nature Medicine, 2018, 24, 1157-1166.	30.7	63
40	Metabolic dependencies and vulnerabilities in leukemia. Genes and Development, 2019, 33, 1460-1474.	5.9	63
41	Covalent inhibition of NSD1 histone methyltransferase. Nature Chemical Biology, 2020, 16, 1403-1410.	8.0	52
42	Synergistic antileukemic therapies in NOTCH1 -induced T-ALL. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2006-2011.	7.1	50
43	Therapeutic targeting of HES1 transcriptional programs in T-ALL. Blood, 2015, 125, 2806-2814.	1.4	40
44	Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. Cancer Cell, 2018, 34, 136-147.e6.	16.8	39
45	Can one target T-cell ALL?. Best Practice and Research in Clinical Haematology, 2018, 31, 361-366.	1.7	37
46	Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood, 2015, 126, 2479-2483.	1.4	36
47	MMP-25 Metalloprotease Regulates Innate Immune Response through NF-ÎºB Signaling. Journal of Immunology, 2016, 197, 296-302.	0.8	34
48	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 1113-1127.	13.2	32
49	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. Journal of Experimental Medicine, 2018, 215, 197-216.	8.5	30
50	MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia, 2021, 35, 3394-3405.	7.2	28
51	GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia. Cancer Discovery, 2019, 9, 1774-1791.	9.4	27
52	The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia. Leukemia, 2018, 32, 1984-1993.	7.2	26
53	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nature Communications, 2022, 13, 2801.	12.8	25
54	The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a035246.	6.2	23

#	Article	IF	Citations
55	Targeting S100A9â€“ALDH1A1â€“Retinoic Acid Signaling to Suppress Brain Relapse inEGFR-Mutant Lung Cancer. Cancer Discovery, 2022, 12, 1002-1021.	9.4	22
56	DNA Microarrays in the Diagnosis and Management of Acute Lymphoblastic Leukemia. International Journal of Hematology, 2004, 80, 395-400.	1.6	21
57	FYNâ€“TRAF3IP2 induces NF-ÎºB signaling-driven peripheral T-cell lymphoma. Nature Cancer, 2021, 2, 98-113.	13.2	19
58	Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7773-7778.	7.1	18
59	Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia. Blood, 2020, 135, 921-933.	1.4	17
60	PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia. Cancer Discovery, 2022, 12, 186-203.	9.4	17
61	SOX11 is a mantle cell lymphoma oncogene. Blood, 2013, 121, 2169-2170.	1.4	16
62	Tumor Suppressor HIPK2 Regulates Malignant Growth via Phosphorylation of Notch1. Cancer Research, 2016, 76, 4728-4740.	0.9	16
63	Transcriptional Regulatory Networks Downstream of NOTCH1 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 740-740.	1.4	15
64	Small Molecule that Reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia (T-ALL). ACS Medicinal Chemistry Letters, 2014, 5, 754-759.	2.8	14
65	Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. Cancer Discovery, 2022, 12, 856-871.	9.4	13
66	Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral TÂcell lymphoma. Cell Reports, 2022, 39, 110695.	6.4	13
67	Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2021, 141, 2908-2920.e7.	0.7	12
68	Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 2022, 13, 1048.	12.8	12
69	Combinatorial ETS1-Dependent Control of Oncogenic NOTCH1 Enhancers in T-cell Leukemia. Blood Cancer Discovery, 2020, 1, 178-197.	5.0	11
70	A Case of Tâ€cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. Pediatric Blood and Cancer, 2016, 63, 1660-1663.	1.5	10
71	Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally. Cancer Cell, 2018, 34, 869-871.	16.8	10
72	ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. Blood, 2022, 139, 399-412.	1.4	10

#	Article	IF	Citations
73	The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.. Blood, 2009, 114, 142-142.	1.4	8
74	Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL.. Blood, 2009, 114, 366-366.	1.4	8
75	Oncogenic AKT Signaling Negatively Regulates Glucocorticoid Receptor Function to Promote Glucocorticoid Resistance In T Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 11-11.	1.4	8
76	Identification of TAL1/SCL Target Genes through siRNA and Microarray Expression Analysis.. Blood, 2004, 104, 4294-4294.	1.4	8
77	Targeted cellular immunotherapy for T cell malignancies. Nature Medicine, 2017, 23, 1402-1403.	30.7	7
78	Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures. Cell Reports, 2020, 30, 3280-3295.e6.	6.4	7
79	Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition. Blood, 2018, 132, 4020-4020.	1.4	7
80	Genome-Wide Transcriptional Regulatory Networks Downstream of TAL1/SCL in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 416-416.	1.4	7
81	Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL. Blood, 2022, , .	1.4	7
82	Gene expression profiling: will it complement or replace immunophenotyping?. Best Practice and Research in Clinical Haematology, 2003, 16, 645-652.	1.7	5
83	Aberrant Cytokine Production by Nonmalignant Cells in the Pathogenesis of Myeloproliferative Tumors and Response to JAK Inhibitor Therapies. Cancer Discovery, 2015, 5, 234-236.	9.4	5
84	Targeting NOTCH1 in T-ALL: Starving the dragon. Cell Cycle, 2016, 15, 483-484.	2.6	5
85	Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Leukemia, 2022, 36, 583-587.	7.2	5
86	MEF2C as Novel Oncogene for Early T-Cell Precursor (ETP) Leukemia. Blood, 2010, 116, 9-9.	1.4	5
87	An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL. Blood, 2012, 120, 285-285.	1.4	5
88	Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models. Blood, 2019, 134, 3870-3870.	1.4	5
89	Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leukemia. Trends in Immunology, 2021, 42, 418-431.	6.8	4
90	Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL.. Blood, 2007, 110, 151-151.	1.4	4

#	Article	IF	Citations
91	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. Blood, 2010, 116, 851-851.	1.4	4
92	Notch Signaling Is Required for Mast Cell Development in the Zebrafish.. Blood, 2009, 114, 3588-3588.	1.4	4
93	Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL. Blood, 2008, 112, 298-298.	1.4	3
94	Activating Mutations In Fyn Kinase In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 811-811.	1.4	3
95	De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL. Blood, 2015, 126, 2627-2627.	1.4	2
96	Mutational Loss of PTEN Induces Resistance to NOTCH1 Inhibition in T-ALL.. Blood, 2007, 110, 5-5.	1.4	2
97	Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor. Blood, 2020, 136, 18-20.	1.4	2
98	Recurrent Rhoa Mutations In Peripheral T-Cell Lymphoma. Blood, 2013, 122, 846-846.	1.4	1
99	A New Recurrent 9q34 Duplication in Pediatric T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 89-89.	1.4	1
100	ETV6 Is An Early T-Cell Progenitor (ETP) Specific Tumor Suppressor Gene in Adult T-ALL. Blood, 2011, 118, 406-406.	1.4	1
101	Therapeutic Utility of PI3KÎ³ Inhibition in Leukemogenesis and Tumor Cell Survival. Blood, 2012, 120, 1492-1492.	1.4	1
102	Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism. Blood, 2019, 134, 806-806.	1.4	1
103	The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL. Blood, 2020, 136, 20-20.	1.4	1
104	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
105	Current perspectives in Tâ€ALL. HemaSphere, 2019, 3, 181-183.	2.7	0
106	Activating Notch1 Mutations Are an Early Event in T-Cell Malignancy of Ikaros Point Mutant Mice.. Blood, 2005, 106, 2616-2616.	1.4	0
107	Microarray Analyses in a Case-Control Cohort of T-ALL Samples Identifies Gene Signature of Potential Prognostic Significance.. Blood, 2005, 106, 1448-1448.	1.4	0
108	Identification of Oncogenic Pathways of T-Acute Lymphoblastic Leukemia (T-ALL) through Gene Expression Profiling of Mouse Tumor Models.. Blood, 2006, 108, 2234-2234.	1.4	0

#	Article	IF	Citations
109	Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol. Blood, 2008, 112, 2548-2548.	1.4	0
110	Challenges and Opportunities for Effective NOTCH1 Targeting in T-ALL.. Blood, 2008, 112, sci-30-sci-30.	1.4	0
111	Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL. Blood, 2008, 112, 200-200.	1.4	0
112	Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 141-141.	1.4	0
113	Redundancy and Specificity of the Metalloprotease System Mediating Oncogenic NOTCH1 Activation in T-ALL.. Blood, 2009, 114, 988-988.	1.4	0
114	Notch Signaling Is Required for Mast Cell Development In the Zebrafish and May Represent a Novel Therapeutic Strategy In Systemic Mastocytosis. Blood, 2010, 116, 930-930.	1.4	0
115	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	1.4	0
116	Identification of a Novel T-ALL Entity with NKX2-1/NKX2-2 Rearrangements. Blood, 2010, 116, 3139-3139.	1.4	0
117	Identification of NOTCH1-Controlled Transcriptional Programs In Human T-Cell Development. Blood, 2010, 116, 2495-2495.	1.4	0
118	Using the Zebrafish As a Tool for Modeling Systemic Mastocytosis,. Blood, 2011, 118, 3208-3208.	1.4	0
119	Familial and Acquired SH2B3 mutations in ALL. Blood, 2012, 120, 1326-1326.	1.4	0
120	Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 294-294.	1.4	0
121	Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy. Blood, 2016, 128, 889-889.	1.4	0
122	Suppression of GATA3 Binding Drives Selective Abrogation of NOTCH1-MYC Enhancer Activity By Nucleosome Invasion in Thymocyte Development and Leukemia. Blood, 2018, 132, 545-545.	1.4	0
123	Expression of Vav1-Myo1F Fusion Affects T-Cell Differentiation and Induces T-Cell Lymphoma. Blood, 2020, 136, 4-4.	1.4	0
124	Mechanisms of Therapeutic Response to Tipifarnib in a Mouse Model of Angioimmunoblastic T-Cell Lymphoma. Blood, 2020, 136, 9-9.	1.4	0